信邦製藥(002390.SZ):2021年度淨利預增50%-65%
格隆匯1月24日丨信邦製藥(002390.SZ)公佈2021年度業績預吿,公司預計2021年度歸屬於上市公司股東的淨利潤為2.60億元-2.86億元,比上年同期增長50%-65%;扣除非經常性損益後的淨利潤2.79億元-3.08億元,比上年同期增長40%-55%;基本每股收益0.15元/股-0.16元/股。
業績變動原因:
1、主營業務影響:
(1)公司2021年醫藥流通、醫療服務、醫藥製造三大業務板塊的主營業務收入較上年度均穩步增長,運營效率逐漸提升,盈利能力提高。(2)新冠疫情對公司2020年一季度經營影響較大,2021年除局部零星疫情的影響外,公司經營活動基本正常。
2、股份支付費用影響:公司2021年9月完成股票期權激勵計劃授予登記工作,2021年度確認的股份支付費用(税後)約為1380萬元。
3、非經常性損益影響:2021年歸屬於上市公司股東的非經常性損益金額約為人民幣2000萬元,主要為:對外捐贈支出2757萬元、政府補助收益737萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.